|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Martel CL, Gumerlock PH, Meyers FJ and
Lara PN: Current strategies in the management of hormone refractory
prostate cancer. Cancer Treat Rev. 29:171–187. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berridge MJ, Lipp P and Bootman MD: The
versatility and universality of calcium signalling. Nat Rev Mol
Cell Biol. 1:11–21. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsavaler L, Shapero MH, Morkowski S and
Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in
prostate cancer and other malignancies and shares high homology
with transient receptor potential calcium channel proteins. Cancer
Res. 61:3760–3769. 2001.
|
|
5
|
Henshall SM, Afar DE, Hiller J, et al:
Survival analysis of genome-wide gene expression profiles of
prostate cancers identifies new prognostic targets of disease
relapse. Cancer Res. 63:4196–4203. 2003.PubMed/NCBI
|
|
6
|
Zhang L and Barritt GJ: Evidence that
TRPM8 is an androgen-dependent Ca2+ channel required for
the survival of prostate cancer cells. Cancer Res. 64:8365–8373.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang ZH, Wang XH, Wang HP and Hu LQ:
Effects of TRPM8 on the proliferation and motility of prostate
cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brawer MK, Deering RE, Brown M, Preston SD
and Bigler SA: Predictors of pathologic stage in prostatic
carcinoma. The role of neovascularity. Cancer. 73:678–687. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrer FA, Miller LJ, Andrawis RI, et al:
Vascular endothelial growth factor (VEGF) expression in human
prostate cancer: in situ and in vitro expression of VEGF by human
prostate cancer cells. J Urol. 157:2329–2333. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jackson MW, Bentel JM and Tilley WD:
Vascular endothelial growth factor (VEGF) expression in prostate
cancer and benign prostatic hyperplasia. J Urol. 157:2323–2328.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borre M, Nerstrom B and Overgaard J:
Association between immunohistochemical expression of vascular
endothelial growth factor (VEGF), VEGF-expressing
neuroendocrine-differentiated tumor cells, and outcome in prostate
cancer patients subjected to watchful waiting. Clin Cancer Res.
6:1882–1890. 2000.
|
|
13
|
Warri AM, Huovinen RL, Laine AM,
Martikainen PM and Harkonen PL: Apoptosis in toremifene-induced
growth inhibition of human breast cancer cells in vivo and in
vitro. J Natl Cancer Inst. 85:1412–1418. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parsons JT, Slack-Davis J, Tilghman R and
Roberts WG: Focal adhesion kinase: targeting adhesion signaling
pathways for therapeutic intervention. Clin Cancer Res. 14:627–632.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang YM, Kung HJ and Evans CP:
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia.
9:90–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Voets T, Owsianik G and Nilius B: Trpm8.
Handb Exp Pharmacol. 329–344. 2007. View Article : Google Scholar
|
|
17
|
Gkika D, Flourakis M, Lemonnier L and
Prevarskaya N: PSA reduces prostate cancer cell motility by
stimulating TRPM8 activity and plasma membrane expression.
Oncogene. 29:4611–4616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liotta LA, Steeg PS and Stetler-Stevenson
WG: Cancer metastasis and angiogenesis: an imbalance of positive
and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrer FA, Miller LJ, Lindquist R, et al:
Expression of vascular endothelial growth factor receptors in human
prostate cancer. Urology. 54:567–572. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mazzucchelli R, Montironi R, Santinelli A,
Lucarini G, Pugnaloni A and Biagini G: Vascular endothelial growth
factor expression and capillary architecture in high-grade PIN and
prostate cancer in untreated and androgen-ablated patients.
Prostate. 45:72–79. 2000. View Article : Google Scholar
|
|
21
|
Hollingsworth HC, Kohn EC, Steinberg SM,
Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage
ovarian carcinoma. Am J Pathol. 147:33–41. 1995.PubMed/NCBI
|
|
22
|
Weidner N, Carroll PR, Flax J, Blumenfeld
W and Folkman J: Tumor angiogenesis correlates with metastasis in
invasive prostate carcinoma. Am J Pathol. 143:401–409.
1993.PubMed/NCBI
|
|
23
|
Kosaka T, Miyajima A, Takayama E, et al:
Angiotensin II type 1 receptor antagonist as an angiogenic
inhibitor in prostate cancer. Prostate. 67:41–49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka S, Haruma K, Tatsuta S, et al:
Proliferating cell nuclear antigen expression correlates with the
metastatic potential of submucosal invasive colorectal carcinoma.
Oncology. 52:134–139. 1995. View Article : Google Scholar
|
|
25
|
Lacoste J, Aprikian AG and Chevalier S:
Focal adhesion kinase is required for bombesin-induced prostate
cancer cell motility. Mol Cell Endocrinol. 235:51–61. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slack JK, Adams RB, Rovin JD, Bissonette
EA, Stoker CE and Parsons JT: Alterations in the focal adhesion
kinase/Src signal transduction pathway correlate with increased
migratory capacity of prostate carcinoma cells. Oncogene.
20:1152–1163. 2001. View Article : Google Scholar : PubMed/NCBI
|
